HYPERTROPHIC CARDIOMYOPATHY (HCM)
Clinical trials for HYPERTROPHIC CARDIOMYOPATHY (HCM) explained in plain language.
Never miss a new study
Get alerted when new HYPERTROPHIC CARDIOMYOPATHY (HCM) trials appear
Sign up with your email to follow new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart drug mavacamten shows promise in thick heart muscle disease
Disease control CompletedThis study looked at 222 adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick and blocks blood flow. Researchers compared those who took the drug mavacamten to those on standard therapy. The main goal was to see if mavacamten could …
Matched conditions: HYPERTROPHIC CARDIOMYOPATHY (HCM)
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New heart drug shows promise in thick heart muscle trial
Disease control CompletedThis study tested a new drug called CK-3773274 (aficamten) in 96 adults with symptomatic hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal was to find the best dose that is safe and improves heart function. Participants received either …
Matched conditions: HYPERTROPHIC CARDIOMYOPATHY (HCM)
Phase: PHASE2 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC